Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patent accidently took the fourth capsule without the gap in between doses; Case reference number US-BN-2025-001417 is a spontaneous case initially received from nurse via Communications (reference number: USBAV25-2058) on 18-Aug-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication were not provided. On an unspecified date, the patient took three capsules of Vivotif vaccine every other day (batch number: unknown) at unknown doses, orally for unknown indication. The patient accidently took the fourth capsule without the gap in between doses (explicitly coded as 'inappropriate schedule of product administration'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age took three capsules of Vivotif vaccine every other day for unknown indication. The patient accidently took the fourth capsule without the gap in between doses, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took three capsules of Vivotif vaccine every other day for unknown indication. The patient accidently took the fourth capsule without the gap in between doses, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.